For the quarter ending 2025-09-30, DAWN made $39,795,000 in revenue. -$19,726,000 in net income. Net profit margin of -49.57%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 39,795,000 | 33,908,000 | 30,761,000 | 12,466,666.667 |
| Cost of product and license revenue | 4,480,000 | 3,765,000 | - | - |
| Research and development | 31,419,000 | 36,149,000 | 39,619,000 | 64,713,000 |
| Selling, general and administrative | 28,147,000 | 28,968,000 | 29,325,000 | 28,826,000 |
| Cost of product revenue | - | - | 2,884,000 | 1,229,666.667 |
| Total cost and operating expenses | 64,046,000 | 68,882,000 | 71,828,000 | 94,768,666.667 |
| Loss from operations | -24,251,000 | -34,974,000 | -41,067,000 | -82,302,000 |
| Gain from sale of priority review voucher | 0 | 0 | - | 36,000,000 |
| Investment income, net | 4,559,000 | 4,671,000 | 5,094,000 | 4,793,000 |
| Other expense, net | -34,000 | -19,000 | -23,000 | 6,666.667 |
| Total non-operating income, net | 4,525,000 | 4,652,000 | 5,071,000 | 40,799,666.667 |
| Loss before income taxes | 19,726,000 | 30,322,000 | 35,996,000 | 41,502,333.333 |
| Income tax expense | 0 | 0 | - | 2,675,333.333 |
| Net loss | -19,726,000 | -30,322,000 | -35,996,000 | -44,177,666.667 |
| Earnings per share, basic | -0.19 | -0.29 | -0.35 | -0.467 |
| Earnings per share, diluted | -0.19 | -0.29 | -0.35 | -0.467 |
| Weighted average number of shares outstanding, basic | 103,381,315 | 103,069,154 | 102,710,382 | -1,129,642.667 |
| Weighted average number of shares outstanding, diluted | 103,381,315 | 103,069,154 | 102,710,382 | -1,234,521.333 |
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)